PHASE II TRIAL OF HIGH-DOSE GEMCITABINE/BUSULFAN/MELPHALAN WITH AUTOLOGOUS STEM-CELL TRANSPLANTATION FOR PRIMARY REFRACTORY OR POOR-RISK RELAPSED HODGKIN’S LYMPHOMA